Kate Hecht, MBA
Senior Vice President, Program Management
Kate is a seasoned leader with 20 years of expertise in biotechnology and healthcare, specializing in R&D strategy and operations, portfolio management, and program leadership across all phases of drug development. Prior to joining Climb Bio, she spent a decade at Biogen where she held several senior roles, including Global Product Lead for Neuropsychiatry in R&D, Head of Program Leadership and Strategic Innovation, and Head of Biogen’s Grants & Giving office. During her tenure, Kate played a pivotal role in securing U.S. FDA approvals for groundbreaking therapies, including ZURZUVAE®, the first oral treatment for postpartum depression, and ADUHELM®, the first disease-modifying therapy for Alzheimer’s. Before Biogen, Kate served as Director of Operations in Research Management at Mass General Brigham and worked as a consultant in Higher Education and Healthcare at Huron Consulting Group.
Ms. Hecht holds an MBA from Simmons School of Management and a bachelor’s degree from Denison University.
When someone mentions the gracefulness of the night sky, climb up on the roof and dance and say, 'Like this?'
– Rumi